The therapeutic role of Меларена is considered relevant in conditions where functional stability becomes affected by sleep timing issues, which leads to characteristic sleep disturbances. Its application is focused on managing related symptomatic burden. The medication is utilized in the management of specific, diagnosed sleep issues.

Uses, Symptoms, and Patient Benefits

Меларена is commonly used across conditions presenting with episodic or chronic timing issues, including Circadian Rhythm Sleep-Wake Disorders, Delayed Sleep-Wake Phase Disorder (DSWPD), and the acute disruption of Jet Lag. It is also applied in managing the symptom cluster of increased sleep-onset latency (difficulty falling asleep) and poor quality of sleep in older adults (aged 55 and over). The medication is applied in addressing symptom clusters that may become intense or disruptive, which may assist with maintaining functional stability related to the sleep-wake cycle.

The benefit is centered on easing the symptomatic burden of mistimed sleep, especially in scenarios like shift work or transcontinental travel. As a patient-oriented benefit, it helps ease the overall symptom burden and supports patients during difficult episodes by easing distress.

This application provides supportive relief when symptoms interfere with routine activities related to schedule changes.

Quick Fact: Relief for Timing Disruption
Symptom Relieved	Increased sleep-onset latency, poor sleep quality, sleep timing misalignment.
Primary Benefit	Contributes to improved comfort during symptomatic periods.
Relevant Clinical Contexts	Intrinsic circadian disorders (DSWPD), situational challenges (Jet Lag, Shift Work).

Regulatory References

1. European Medicines Agency (EMA) review on Melatonin Neurim

Who Can and Cannot Use Меларена?

The eligibility for Меларена is strictly defined by regulatory guidelines based on age, specific conditions, and underlying health status.

Population Status	Regulatory Rule
Approved Use	Adults ge 55 are licensed for short-term primary insomnia, and Adults for the treatment of jet lag. Use is also permitted in specific pediatric sub-groups, such as children aged 6–17 with ASD or ADHD-related insomnia, under certain product labels.
Absolute Prohibition	The medicine is contraindicated in patients with a known hypersensitivity to the active substance (melatonin) or excipients. This also applies to individuals with certain hereditary metabolic disorders (e.g., total lactase deficiency) due to excipient content.
Not Recommended	Use is not recommended for women who are pregnant or breastfeeding. It is also not recommended for patients with hepatic impairment (liver disease), severe renal impairment (kidney disease), or autoimmune diseases due to limited safety data or clearance concerns.
Limited/Conditional Use	The safety and efficacy are not yet established for the general pediatric population. Caution is advised for patients with epilepsy and for those with non-severe renal impairment.

This regulatory profile establishes clear boundaries, restricting use to defined adult populations and excluding individuals based on pre-existing conditions or physiological status where safety data is limited or clearance is impaired.

Melarena (melatonin) has the potential to interact with several classes of medicines, either by altering the effects of the co-administered drug or by affecting the concentration of melatonin itself. It is essential to inform your healthcare provider of all prescription medications, over-the-counter products, and supplements you are taking.

Key Interactions

Drug Class	Example Medications	Potential Interaction	Recommendation
Anticoagulants	Warfarin	May increase the anticoagulant effect, raising the risk of bleeding.	Close monitoring of coagulation parameters (e.g., INR) is necessary.
CNS Depressants	Benzodiazepines, Opioid pain relievers, Alcohol	Can cause an additive sedative effect, leading to excessive drowsiness.	Use with caution; avoid combining with alcohol.
Antihypertensives	Nifedipine	May decrease the blood pressure-lowering effect of the antihypertensive medication.	Blood pressure should be monitored.
CYP1A2 Inhibitors	Fluvoxamine	Significantly increases melatonin blood levels, which can lead to excessive drowsiness and effects.	The combination is generally not recommended.
Contraceptives	Estrogen-containing oral contraceptives	May increase the effects and side effects of melatonin by raising its concentration.	Monitor for increased side effects.
Immunosuppressants	Cyclosporine	Melatonin may stimulate immune function, potentially interfering with immunosuppressive therapy.	Use with caution.

Simultaneous use with alcohol should be avoided as it may enhance the sedative effects of melatonin. Always consult your doctor or pharmacist before starting or stopping any medication while taking Melarena.

The mechanism of action for Меларена (Melatonin) is defined by its highly specific action as a Melatonin receptor agonist, targeting the brain's master biological clock and the pathways that govern the induction of rest-phase physiology.

Central Chronobiotic Action and Circadian Alignment

The drug primarily activates the Melatonin Receptor 2 ( MT2) in the Suprachiasmatic Nucleus (SCN). This interaction is central to its chronobiotic action, involving a Gi-protein-mediated molecular cascade that suppresses neuronal firing. This mechanism phase-advances the circadian rhythm, which is required for the stabilization and alignment of the body's internal 24-hour cycle.

Induction of Sleep Propensity

Simultaneously, the drug acts as an agonist at the Melatonin Receptor 1 ( MT1), which initiates a molecular sequence that signals the biological onset of night. By directly suppressing the output of wake-promoting SCN neurons, the mechanism decreases the intensity of SCN-mediated wake signaling and establishes the physiological state of sleep propensity.

Regulation of Core Body Temperature

Melatonin's mechanism also modulates autonomous physiological responses, including central thermoregulation. By promoting peripheral vasodilation, the drug induces a decrease in core body temperature, which is a fundamental biological change that accompanies and is required for the natural initiation of rest-phase physiology.

Меларена is administered exclusively via the oral route as a fixed 2 mg prolonged-release tablet once daily. This specific dosage strength is the standard and also represents the maximum daily dose specified for this formulation. The medication is to be taken after food to facilitate its absorption and intended effect.

Proper usage requires precise timing: the single daily dose must be consumed 1 to 2 hours before the patient’s intended bedtime. This timing is essential for coordinating the drug’s release profile with the body’s circadian rhythm. To maintain the necessary prolonged-release characteristics, the tablet must be swallowed whole and must not be chewed, cut, or crushed under any circumstances.

The standard usage protocol applies primarily to older adults aged 55 and over. The medication is generally not recommended for use in individuals under 18 years of age due to a lack of established safety data, nor is it recommended for patients with hepatic impairment. The treatment is intended for short-term use for a duration of up to thirteen weeks.

Research on the Compound’s Profile

Research has explored the effects of the compound Melatonin, the active substance in Меларена, on conditions related to the sleep-wake cycle. Research explored the compound's behavior in laboratory settings, which suggests a role in signaling the onset of darkness.

Studies Exploring Effects and Outcomes

Clinical trials examined whether the compound might relate to changes in sleep metrics, primarily in individuals with specific sleep disturbances. The compound's form used in studies was for oral administration.

• Sleep Onset: Evidence from meta-analyses suggests that, in select populations, the use of the compound may be associated with a statistically significant reduction in the time taken to fall asleep.
• Total Sleep Time: Findings regarding the compound's effect on total sleep duration have been mixed across various trials and populations.
• Research Focus: Studies have also explored the compound's activity at a cellular level, and research is ongoing into its potential effects on conditions like neurodegenerative disorders, pain syndromes, and metabolic function, although definitive clinical conclusions are not yet established.

---

Side Effects and Safety Data

Research into safety has documented the compound as generally well-tolerated in short-term use. Studies have focused on the compound's effects on systems including the liver and kidneys, often excluding individuals with pre-existing conditions from the trial populations.

• Common Reports: Studies documented that the most frequently reported adverse effects in clinical trials involved gastrointestinal issues, temporary fatigue, and dry mouth. These reports were frequently documented in the study records.
• Serious Reports: Reported side effects, while rare in studies, included persistent dizziness and an increased heart rate. These observations led to some participants discontinuing the study treatment.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE) Clinical Guideline: Sleep Disorders

Common questions about Меларена (FAQ)

Q: How quickly does Меларена start working after taking it?

The tablet is a prolonged-release formulation, meaning the active substance is released slowly over several hours. Regulatory guidance describes that the medicine is typically administered 1 to 2 hours before the patient's intended bedtime to align with the body’s natural cycle.

Q: Does Меларена make you feel groggy or tired the next day?

Official product information lists somnolence (sleepiness) as a common side effect. The medicine may have a moderate influence on the ability to perform skilled tasks, such as driving, for several hours after administration. This underscores the importance of considering the timing of the dose relative to activities that require full alertness.

Q: Can Меларена affect my mood or behavior?

Regulatory documents state that certain changes in mood are possible. Specifically, official adverse event listings include irritability as an uncommon side effect and, in rare cases, temporary depression has been reported.

Q: Is it normal to have vivid dreams when using Меларена?

Official documentation for the active substance indicates that changes in sleep quality can occur. Both abnormal dreams and nightmares are documented as uncommon side effects.

Q: Will Меларена cause withdrawal symptoms if I stop taking it?

The medication is authorized for short-term use. Clinical studies examining discontinuation after short-term treatment have not reported signs of rebound insomnia or withdrawal symptoms.

Q: Is Меларена considered a sleeping pill or a sedative?

Меларена is classified as a Melatonin receptor agonist. Its action is focused on regulating the body's internal circadian rhythm to control the timing of sleep, rather than being classified as a non-specific sedative agent.

Q: Does Меларена have any effect on blood pressure?

Yes, official documentation lists changes in blood pressure, specifically hypertension (high blood pressure) or hypotension (low blood pressure), as an uncommon side effect. Caution is also advised when combining it with certain antihypertensive (blood pressure lowering) medications due to interaction risks.

Q: Can Меларена be taken with common pain relievers like ibuprofen or paracetamol?

The regulatory guidance on interactions is extensive. It is advised that use with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may increase the risk of side effects, including enhancing the sedative effects. It is important to inform a healthcare provider of all medicines being taken.

Q: Are there any specific foods or drinks to avoid when using Меларена?

Official documentation states the medicine is to be taken after food to facilitate its proper absorption. Furthermore, official product information advises against the simultaneous use of alcohol, as it may enhance the sedative effects of the medicine.

Q: Is there a risk of becoming dependent on Меларена?

No signs of dependence, such as withdrawal or rebound effects, have been reported in clinical studies following the cessation of short-term treatment with this product.

Q: What happens if I occasionally miss a dose of Меларена?

According to the official patient information, if a dose is forgotten, regulatory guidance indicates that it should be skipped. The next scheduled dose would then be taken at the usual time the following night. Official guidance cautions against taking two doses to compensate for a missed dose.

Q: Are there research studies looking at the long-term effects of Меларена?

The treatment is authorized for short-term use, typically up to 13 weeks. Official documents confirm that research into long-term effects of the active substance is ongoing, particularly concerning its potential in other fields like neurodegenerative disorders.

Q: Is it true that Меларена can interact with medicines for depression or anxiety?

Yes, regulatory product labels warn of potential interactions. This includes a specific warning about CYP1A2 inhibitors, which include some medicines for depression, and caution is also advised with CNS depressants, a class that includes certain anxiety medications.

Q: Does using Меларена mean I will fall asleep instantly?

The medication is not an immediate sedative. It is a circadian rhythm regulator that must be taken 1 to 2 hours before the intended bedtime. Its mechanism is to signal the body’s readiness for sleep, not to cause instant unconsciousness.

Q: Is it possible for Меларена to make an existing condition worse?

Official guidance states that the medicine is not recommended for patients with certain pre-existing conditions, including autoimmune diseases, severe liver problems, and severe kidney problems, as its use in these populations may carry additional, unstudied risks.

Q: Does the manufacturer recommend any blood tests while using Меларена?

While not a general requirement, the regulatory documents specify that if a patient is taking certain blood-thinning medicines (anticoagulants), close monitoring of blood coagulation parameters is necessary due to a potential interaction.

Q: Can Меларена be taken if I am already taking herbal supplements?

Official regulatory guidance advises general caution with other supplements. It specifically recommends avoiding herbal remedies that are known to cause drowsiness, as combining them with this medicine may enhance its sedative effects.

Q: What are the signs of taking too much Меларена?

In the event of taking too much, official reports indicate that symptoms may include severe drowsiness, headache, dizziness, nausea, and vomiting. Official guidance states that immediate medical attention is necessary if an overdose is suspected.

Q: How long does it take for the substance in Меларена to leave the body?

The active substance, Melatonin, has a short terminal elimination half-life, which is around 3.5 to 4 hours following administration of the prolonged-release tablet. This period indicates how long it takes for the substance's concentration in the body to be significantly reduced.

Q: Does Меларена influence hormone levels in men or women?

Melatonin is structurally an endogenous hormone, and regulatory documents note that it can influence the secretion of gonadotropins, which are necessary for the production of reproductive hormones. For safety, the medicine is not recommended for women who are pregnant or breastfeeding.

Q: Why do some people report feeling colder or warmer after taking Меларена?

The drug's mechanism of action involves modulation of central thermoregulation. This includes promoting peripheral vasodilation, which is a process that induces a decrease in core body temperature and is a fundamental biological change required for sleep initiation.

Q: What is the difference in effect between a low dose and a high dose of Меларена?

The only recommended dosage is the fixed 2 mg prolonged-release tablet, which is also the maximum daily dose. Clinical studies have shown that higher doses are generally not associated with increased effectiveness but may be linked to a higher risk of side effects.

Q: What are the descriptive facts about Меларена's potential effect on immunity?

The official label notes that the medicine may stimulate immune function, and caution is advised regarding its use with certain immunosuppressive therapies. Due to safety concerns, the product is not recommended for use in patients who have been diagnosed with autoimmune diseases.

The storage and disposal of Меларена (Melatonin) must adhere strictly to the conditions documented in official regulatory labeling.

Storage Conditions

Melarena must be stored at a temperature not exceeding 30 C and should be protected from both light and moisture. To maintain product integrity and stability, the medicine must be kept in the original container until use. A mandatory requirement is to keep this medicine out of the sight and reach of children.

Handling and Disposal

The product must not be used after the expiry date printed on the packaging. For disposal, unused or expired Меларена must not be thrown away via wastewater or household waste. Instead, the medicine should be disposed of according to local requirements for pharmaceutical waste return, as defined by official regulatory protocols.